About The Study: This cross-sectional study found an increase in glucagon-like peptide 1 receptor agonist (GLP-1RA) prescriptions, with notable differences across subpopulations by insurance type, sex, and age. Tirzepatide and semaglutide grew the fastest, possibly due to their superior glycemic, weight loss, and guideline-emphasized cardiorenal benefits. Although GLP-1RAs are generally covered for type 2 diabetes (T2D), coverage for obesity is limited (e.g., Medicare excludes anti-obesity drugs). Off-label semaglutide (for T2D) use in the obesity-only group underscores access barriers.
Corresponding Authors: To contact the corresponding authors, email Mohammed K. Ali, MD, MBA ( mkali@emory.edu ) and Hui Shao, MD, PhD ( hui.shao@emory.edu ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.40890)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.40890?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103125
JAMA Network Open